-
AbbVie and Calibr Announce Strategic Collaboration to Advance Preclinical Research
•
AbbVie (NYSE: ABBV) and US-based Calibr, the nonprofit drug discovery division of San Diego research institute Scripps Research, have unveiled a strategic collaboration aimed at advancing preclinical research. This partnership builds on previous work with Scripps that has already led to the development of several preclinical and early clinical drug…
-
ArkBio and Calibr Renew Collaboration to Develop First-in-Class Respiratory Drug AK0705
•
Shanghai Ark Biopharmaceutical Co., Ltd announced that it has renewed its co-development collaboration with Calibr, a division of Scripps Research, to develop AK0705, a potential first-in-class drug targeting an enzyme that plays a crucial role in respiratory inflammation. The drug is intended to treat a broad spectrum of respiratory diseases,…
